EGFR and non-small cell lung carcinoma: The histologic conversion from EGFR-mutated NSCLC into small cell lung cancer (SCLC) has been recorded in 14% of patients progressing to first-line osimertinib and in 4–15% of patients experiencing disease progression in the second-line setting [6,18,61].